USPTO serial 79368347
AZEMIDITE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Oct 29, 2024
- Examiner
- MANCA, ALBERTO I
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with AZEMIDITE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Zhi Dong
Zhi Dong HSML, P. C.45 South Seventh Street, Suite 2700Minneapolis, MN 55402United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Glucosides being chemicals for industrial purposes; carbonic hydrates; polymer resins, unprocessed; artificial resins, unprocessed; chemical preparations in the nature of ion-exchange resins; enzymes for industrial purposes; enzymes for the food industry; biochemical catalysts; catalysts for chemical processes; industrial chemicals; chemical preparations for scientific purposes, other than for medical or veterinary use; chemical reagents, other than for medical or veterinary purposes; chemical substances for analyses in laboratories, other than for medical or veterinary purposes; chemical preparations for analyses in laboratories, other than for medical or veterinary purposes; cryogenic preparations in solid, liquid or gas state for use in chilling and freezing; diagnostic preparations, other than for medical or veterinary purposes | ACTIVE | — |
| 005 | Medicines for humans for the treatment of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; pharmaceutical preparations for the treatment of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; chemico-pharmaceutical preparations for the treatment of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; vaccines; drugs for medical purposes, namely, pharmaceutical preparations for the treatment of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; biological preparations for medical purposes for the treatment of cardiovascular diseases, metabolic diseases, liver diseases, genetic disordersand rare ocular, respiratory, gastrointestinal, cerebral diseases; chemical preparations for pharmaceutical purposes for the treatment of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; chemical preparations for medical purposes for the treatment of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; diagnostic biomarker reagents for medical purposes; crude drugs being pharmaceutical preparations for the treatment of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; biochemical medicines, namely, antidepressants, appetite suppressants, cardiovascular drugs, antitumor drugs and hypoglycemic drugs; chemical reagents for medical or veterinary purposes; diagnostic preparations for medical purposes; dietetic substances adapted for medical use, namely, dietary supplements and dietetic foods adapted for medical use; depuratives for the body; veterinary preparations for the treatment of gastrointestinal diseases, cardiovascular diseases, metabolic diseases, and liver diseases; pesticides; disinfectant wipes; dressings, medical; composite materials for dental purposes; diapers for pets | ACTIVE | — |
| 040 | Custom assembling of materials for others, namely, custom manufacture of industrial chemicals, pharmaceuticals; providing information relating to material treatment; metal treating; rental of machines and apparatus for processing food; typesetting; recycling of chemicals; processing of chemical reagents for use in manufacture; rental of chemical processing machines; custom manufacturing of make-up | ACTIVE | — |
| 042 | Scientific laboratory services; scientific research; technical writing; technological research in the field of pharmaceutical manufacturing processes and pharmaceutical studies; quality control for others; chemistry services, namely, chemistry consultation, research in the field of chemistry; chemical research and analysis; development and testing of chemical production methods; biochemical research and development; chemistry consultation | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Azemidite Biopharm Co., Ltd.
- Other trademarks owned by Azemidite Biopharm Co., Ltd.
- Other trademarks owned by Azemidite Biopharm Co., Ltd.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 040
- Other trademarks in Class 042
- Similar marks named AZEMIDITE
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 19, 2025 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Mar 31, 2025 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Mar 31, 2025 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jan 29, 2025 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Oct 29, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Oct 29, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Oct 12, 2024 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Sep 25, 2024 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Sep 25, 2024 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Aug 13, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 13, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 24, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 2, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 2, 2024 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jul 2, 2024 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jul 2, 2024 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jul 2, 2024 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| May 28, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 28, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 28, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 26, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| Dec 1, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Nov 30, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Nov 30, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Nov 29, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 24, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| May 2, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Apr 28, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 27, 2023 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |